OUR EXPERIENCE, YOUR QUALITY OF LIFE

Site www.bendavar.com is available with information related to this product and its use, in addition to an online library with many articles of interest to practitioners.

Library

    • Pierre Fenaux

      Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute...

      Open PDF (245 kb)
    • Emmanuel Raffoux

      Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study

      Open DOC (49 kb)
    • GAUTAM BORTHAKUR

      Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk...

      Open PDF (184 kb)
    • D. A. Pollyea

      An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients.

      Open PDF (12 kb)
    • E. Bustinza-Linares

      Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced...

      Open PDF (11 kb)

    • Ronit Gurion

      5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis...

      Open PDF (237 kb)
    • Lewis R. Silverman

      Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by...

      Open PDF (101 kb)
    • Lewis R. Silverman

      Randomi zed Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B...

      Open PDF (184 kb)
    • Pierre Fenaux

      Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes...

      Open PDF (1153 kb)

    • Eric Tse

      Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

      Open PDF (99 kb)
    • Kavita Radhakrishnan

      Leukemia, Myelodysplasia, and Transplantation

      Low day 100 transplant-related mortality (TRM)...

      Open PDF (28 kb)
    • Michael Mathisen

      Leukemia, Myelodysplasia, and Transplantation

      Interim results of a phase I/II randomized study of clofarabine...

      Open PDF (27 kb)
    • A Pession

      Use of clofarabine for acute childhood leukemia

      Open PDF (159 kb)
    • Anjali S. Advani

      Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine and Cytarabine for Relapsed or Refractory Acute...

      Open PDF (586 kb)

    • S Imbergamo

      [P0673] CLOFARABINE AS A SALVAGE THERAPY AND A BRIDGE TO TRANSPLANTATION IN PATIENTS WITH HIGH RISK ACUTE...

      Open DOC (157 kb)
    • Sima Jeha

      Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

      Open PDF (91 kb)
    • Carlos Enrique Vigil

      Leukemia, Myelodysplasia, and Transplantation

      A phase II study of clofarabine and daunorubicin...

      Open PDF (27 kb)
    • EDWARD AGURA

      Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly...

      Open PDF (265 kb)
    • Theresa M Harned Paul S Gaynon

      Treating refractory leukemias in childhood, role of clofarabine

      Open PDF (116 kb)

      Linfoma No Hodgkin

    • ASCO

      Sven De Vos

      A phase III randomized double-blind placebo-controlled study evaluating the LNH

      Open PDF (28 kb)
    • ASCO

      David MacDonald

      Different safety profiles of first-line bendamustine-rituximab (BR) R-CHOP and LNH

      Open PDF (40 kb)
    • ASCO

      Ian Flinn

      Secondary efficacy subanalysis by histology from the phase III BRIGHT study LNH

      Open PDF (38 kb)
    • ASCO

      John Leonard

      Tolerability and activity of combinations of the PI3Kd inhibitor idelalisib (GS-1101) LNH

      Open PDF (32 kb)
    • R. Van der Jagt, P. Laneuville, D. MacDonald y otros.

      A Canadian perspective on bendamustine for the treatmen...

      Open PDF (452 kb) Open PDF II (32 kb)

    • Mathias J Rummel

      Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell...

      Open PDF (312 kb)
    • Remy Gressin

      Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial.

      Open PDF (28 kb)
    • Mathias Rummel, MD, PhD, Giessen, Germany

      Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

      Open PDF (948 kb)
    • Jonathan W. Friedberg

      Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin’s Lymphoma: Results

      Open PDF (117 kb)
    • Brad S. Kahl

      Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma

      Open PDF (185 kb)

    • K. Sue Robinson

      Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent...

      Open PDF (118 kb)

    • E. Weidmann

      Bendamustine is effective in relapsed or refractory aggresive non-Hodgking´s lymphoma

      Open PDF (68 kb)

    • Georg Hess

      697 Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell...

      Open PDF (142 kb)
    • Nathan H. Fowler

      778 Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma

      Open PDF (164 kb)
    • Maurizio Bendandi

      2691 Single Agent Bendamustine Is An Effective Pre-Vaccine Treatment for Patients with Relapsed Follicular Lymphoma

      Open PDF (140 kb)

      Leucemia Linfática Crónica

    • Susan Mary O'Brien

      Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine...

      Open PDF (139 kb)
    • K Holtzer-Goor

      [P1089] Modelling the 10-Year cost effectiveness of Bendamustine as first line treatment...

      Open PDF (596 kb)
    • Georg Guenther

      Bendamustine retreatment of CLL in the outpatient setting.

      Open PDF (35 kb)
    • William G. Wierda

      901 A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmuno-therapy...

      Open PDF (157 kb)
    • Rudolf Weide

      1615 Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas...

      Open PDF (119 kb)

    • Thomas J. Kipps

      3904 Navitoclax (ABT-263) Plus Fludarabine / Cyclophosphamide / Rituximab (FCR)...

      Open PDF (151 kb)

    • Kathryn S. Kolibaba

      3914 Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients ≥70 Years...

      Open PDF (173 kb)
    • Manuela A. Bergmann

      Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia...

      Open PDF (170 kb)
    • Saad Jamshed, Bruce D Cheson

      Role of bendamustine in the treatment of chronic lymphocytic leukemia

      Open PDF (113 kb)
    • Wolfgang U. Knauf,

      Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients...

      Open PDF (146 kb)

    • ASCO

      Herbert Aaron Eradat

      A phase III randomized double-blind placebo-controlled study evaluating the LLC

      Open PDF (31 kb)
    • ASCO

      Jacqueline Claudia Barrientos

      Update on a phase I study of the selective PI3Kd inhibitor idelalisib (GS-1101) in LLC

      Open PDF (32 kb)
    • ASCO

      Betty Y Chang

      Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic LLC.

      Open PDF (28 kb)

      Mieloma Múltiple

    • W Pönisch

      Combined Bendamustine, prednisolone and lenalidomine in patients with refractory or relapsed multiple...

      Open PDF (225 kb)
    • Philippe Rodon

      Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma...

      Open PDF (29 kb)
    • Suzanne Lentzsch

      Bendamustina en Mieloma Múltiple
      304 Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients...

      Open PDF (161 kb)
    • James R. Berenson

      Bendamustina en Mieloma Múltiple
      1857 Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed...

      Open PDF (154 kb)
    • Wolfram Pönisch

      Bendamustina en Mieloma Múltiple
      1933 Impact of Bendamustine Pretreatment on Stem Cell Mobilization and...

      Open PDF (123 kb)

    • Heinz Ludwig

      Bendamustina en Mieloma Múltiple
      2928 Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed...

      Open PDF (167 kb)
    • Wolfram Pönisch

      Bendamustina en Mieloma Múltiple
      2938 Successful Treatment with Bortezomib in Combination with Bendamustine...

      Open PDF (133 kb)
    • Jesus G. Berdeja

      Bendamustina en Mieloma Múltiple
      2943 A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone...

      Open PDF (143 kb)

      Indolentes y del Manto

    • Carlos Visco

      Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma...

      Open DOC (30 kb)
    • Wayne Su

      Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL)...

      Open PDF (27 kb)
    • Georg Hess

      Bendamustina en Linfomas de Manto
      697 Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of...

      Open PDF (142 kb)
    • Mats Jerkeman

      Bendamustina en Linfomas de Manto
      700 Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients...

      Open PDF (140 kb)
    • Michele Magni

      Bendamustina en Linfomas de Manto
      1647 Safety, Tolerability and Activity of Ofatumumab, Bendamustine...

      Open PDF (163 kb)

    • Carlo Visco

      Bendamustina en Linfomas de Manto
      2677 Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen in patients...

      Open PDF (130 kb)
    • Jonathan W. Friedberg

      Bendamustina en Linfomas de Manto
      The combination of bendamustine, bortezomib, and rituximab for patients with relapsed...

      Open PDF (223 kb)
    • K. Sue Robinson

      Bendamustina en Linfomas de Manto
      Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed...

      Open PDF (118 kb)
    • Mathias J. Rummel

      Bendamustina en Linfomas de Manto
      Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of...

      Open PDF (282 kb)
    • ASCO

      Michael Wang

      A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed MCL.

      Open PDF (28 kb)

    • ASCO

      Nina D. Wagner-Johnston

      Preliminary results of PI3Kd inhibitor idelalisib (GS-1101) treatment in combination...

      Open PDF (31 kb)

      EHA-ASH 2013

    • Matthew Woods

      THE EFFICACY AND SAFETY OF FIRST–LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA

      Open PDF (376 kb)
    • Novella Pugliese

      BENDAMUSTINE–BASED THERAPY IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND...

      Open PDF (484 kb)
    • Salvatore Improta

      BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTRÖM'S MACROGLOBULINEMIA

      Open PDF (373 kb)
    • Matteo Pelosini

      LOW DOSE BENDAMUSTINE IN LYMPHOPROLIFERATIVE DISEASE: A SINGLE CENTER EXPERIENCE

      Open PDF (329 kb)
    • Clara De Risi

      SAFETY OF BENDAMUSTINA INCLUDING DHAP REGIMEN AS SALVAGE THERAPY IN MULTIRESISTANT LYMPHOMA PATIENTS

      Open PDF (404 kb)

    • Philippe Rodon

      BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY MM PROGRESSIVE AFTER 1ST LINE THERAPY (IFM 2009–01 TRIAL)

      Open PDF (381 kb)
    • Alessandro Isidori

      BENDAMUSTINE, ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL...

      Open PDF (380 kb)
    • James Brockbank

      A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES, UTILITY, RESOURCE USE, AND COST ESTIMATES OF FIRST–LINE TREATMENTS FOR...

      Open PDF (377 kb)
    • Enrique Ocio San Miguel

      EX VIVO PHARMACOLOGICAL EVALUATION OF 19 DRUGS IN AN AVERAGE OF 50 MULTIPLE MYELOMA PATIENTS USING...

      Open PDF (364 kb)
    • Heinz Ludwig

      TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE BORTEZOMIB DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY

      Open PDF (463 kb)

    • Caterina Patti

      INTENSIFIED PROGRAM INCLUDING BENDAMUSTINE, HIGH DOSE THERAPY AND AUTOGRAFT FOR PATIENTS WITH RELAPSED OR...

      Open PDF (304 kb)
    • Carola Boccomini

      BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R–BM) INDUCTION FOLLOWED BY RITUXIMAB CONSOLIDATION...

      Open PDF (461 kb)
    • Claudio Cerchione

      BENDAMUSTINE : A NEW OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

      Open PDF (298 kb)
    • Takae Kohara

      EVALUATION OF EFFICACY AND SAFETY OF BENDAMUSTINE TREATMENT IN OSAKA LYMPHOMA STUDY GROUP(OLSG)...

      Open PDF (334 kb)
    • Martin Becker

      NON–INTERVENTIONAL STUDY BE–1ST: FIRST LINE THERAPY WITH BENDAMUSTINE IN ADVANCED INDOLENT NON–HODGKIN...

      Open PDF (535 kb)

    • William G. Wierda & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 437

      Open PDF (367 kb)
    • Heinz Ludwig & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 943

      Open PDF (432 kb)
    • Ian W. Flinn & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1624

      Open PDF (423 kb)
    • Francisco Javier Peñalver & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1639

      Open PDF (435 kb)
    • Stefano Sacchi & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1851

      Open PDF (438 kb)

    • Wolfram Poenisch & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1855

      Open PDF (427 kb)
    • Antonella Anastasia & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1914

      Open PDF (431 kb)
    • Mazyar Shadman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2622

      Open PDF (482 kb)
    • Francisco Javier Peñalver & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1639

      Open PDF (435 kb)
    • Carola Boccomini & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2720

      Open PDF (435 kb)

    • Mathias J. Rummel & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2739

      Open PDF (512 kb)
    • Veronique Leblond & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2744

      Open PDF (445 kb)
    • Mazyar Shadman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2622

      Open PDF (482 kb)
    • Georg Günther & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2905

      Open PDF (530 kb)
    • Eric Sanchez & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2952

      Open PDF (432 kb)

    • Pellegrino Musto & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2971

      Open PDF (344 kb)
    • Julie E. Chang & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3647

      Open PDF (432 kb)
    • Antonella Anastasia & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3652

      Open PDF (428 kb)
    • Frederick Lansigan & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3657

      Open PDF (352 kb)
    • Myron S. Czuczman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3662

      Open PDF (438 kb)

    • Wolfgang Ulrich Knauf & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3666

      Open PDF (510 kb)
    • Martin JS Dyer & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3686

      Open PDF (441 kb)
    • Antonio Salar & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3691

      Open PDF (349 kb)
    • Francesco Zaja & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3922

      Open PDF (444 kb)
    • Beatriz Aguado Bueno & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4035

      Open PDF (343 kb)

    • Philippe Rodon & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4044

      Open PDF (432 kb)
    • Jesus G. Berdeja & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4047

      Open PDF (441 kb)
    • Giovanni Palladini & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4057

      Open PDF (433 kb)
    • Damian J. Green & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4126

      Open PDF (432 kb)
    • Stefano Sacchi & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1851

      Open PDF (437 kb)

    • Mazyar Shadman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2622

      Open PDF (482 kb)

      Otros Artículos

    • Carlos Visco

      Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma...

      Open DOC (30 kb)
    • John Leonard

      A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.

      Open PDF (1001 kb)
    • Christine Marie Lovly

      A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).

      Open PDF (25 kb)
    • A de la Fuente

      [P1669] BENDAMUSTINE IN THE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA. A RETROSPECTIVE ANALYSIS IN SPAIN

      Open PDF (124 kb)
    • Christopher Fraser

      Bendamustina en Leucemia Aguda
      3602 Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory...

      Open PDF (151 kb)

    • Jack M. Lionberger

      Bendamustina en LMA
      1552 Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy...

      Open PDF (150 kb)
    • Leukemia Research

      Bendamustina en Linfomas Hodgkin de Alto Grado
      Efficacy of bendamustine as salvage treatment in an heavily pre-treated

      Open PDF (112 kb)
    • Issa F Khouri

      894 Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for...

      Open PDF (143 kb)
    • Anne-Charlotte Dubbelman

      2476 An Open-Label Phase I Pharmacokinetic Study of [14c] Bendamustine in Patients with...

      Open PDF (144 kb)
    • Lorenzo M. Leoni

      Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other...

      Open PDF (483 kb)

    • Lorenzo M. Leoni

      Bendamustine: Rescue of an Effective Antineoplastic Agent From the Mid-Twentieth Century

      Open PDF (534 kb)
    • G Benevolo

      [P0208] SAFETY AND EFFICACY OF BENDAMUSTINE THERAPY IN WALDENSTROM MACROGLOBULINEMIA

      Open PDF (70 kb)
    • ASCO

      Daniel Joseph Allendorf

      Phase I/IIa study of the novel combination of bendamustine with irinotecan followed by etoposide and carboplatin...

      Open PDF (36 kb)

    • David S. Siegel

      A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma...

      Open PDF (550 kb)